New developments in transplant proteomics

Simple item page
dc.contributor.authorHo, Julie
dc.contributor.authorHirt-Minkowski, Patricia
dc.contributor.authorWilkins, John
dc.date.accessioned2020-09-11T21:57:24Z
dc.date.available2020-09-11T21:57:24Z
dc.date.issued2017-05
dc.date.submitted2020-09-11T17:41:17Zen_US
dc.description.abstractPurpose of review: Despite modern immunosuppression, renal allograft rejection remains a major contributor to graft loss. Novel biomarkers may help improve posttransplant outcomes through the early detection and treatment of rejection. Our objective is to provide an overview of proteomics, review recent discovery-based rejection studies, and explore innovative approaches in biomarker development. Recent findings: Urine MMP7 was identified as a biomarker of subclinical and clinical rejection using two-dimensional liquid chromatography tandem–mass spectrometry (LC-MS/MS) and improved the overall diagnostic discrimination of urine CXCL10 : Cr alone for renal allograft inflammation. A novel peptide signature to classify stable allografts from acute rejection, chronic allograft injury, and polyoma virus (BKV) nephropathy was identified using isobaric tag for relative and absolute quantitation (TRAQ) and label-free MS, with independent validation by selected reaction monitoring mass spectrometry (SRM-MS). Finally, an in-depth exploration of peripheral blood mononuclear cells identified differential proteoform expression in healthy transplants versus rejection. Summary: There is still much in the human proteome that remains to be explored, and further integration of renal, urinary, and exosomal data may offer deeper insight into the pathophysiology of rejection. Functional proteomics may be more biologically relevant than protein/peptide quantity alone, such as assessment of proteoforms or activity-based protein profiling. Discovery-based studies have identified potential biomarker candidates, but external validation studies are required.en_US
dc.description.sponsorshipCanadian Institutes of Health Research (CIHR grant 287559). Canadian National Transplant Research Program. CIHR New Investigator Salary Award. Astellas Foundation for Biomedical Research (grant CH-02-RG-248). Gottfried und Julia Bangeter-Rhyner Foundation. Canadian Foundation for Innovation infrastructureen_US
dc.identifier.citationCurr Opin Nephrol Hypertens 26(3): 229-234, 2017en_US
dc.identifier.doi10.1097/MNH.0000000000000319
dc.identifier.urihttp://hdl.handle.net/1993/35052
dc.language.isoengen_US
dc.publisherWolters Kluwer Healthen_US
dc.rightsopen accessen_US
dc.subjectactivity-based protein profilingen_US
dc.subjectaptameren_US
dc.subjectmass spectrometryen_US
dc.titleNew developments in transplant proteomicsen_US
dc.typeresearch articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2017 New developments in transplant proteomics Curr Opin Nephrol HTN.pdf
Size:
140.98 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works